Idera Pharmaceuticals, Inc.

1.4500 4.1900
52 weeks
52 weeks

Mkt Cap 43.43M

Shares Out 28.02M

Send me real-time posts from this site at my email

Mallinckrodt MNK shares slide after hours on restructuring reports; Marinus MRNS and OVID rise on analyst coverage

Price and Volume Movers

Mallinckrodt Plc (NYSE: MNK) shares are trading down 42% to $1.49 after hours on reports by Bloomberg that it is exploring options to absorb potential costs from lawsuits related to the opioid epidemic. The company has hired law firm Latham & Watkins LLP and consulting firm AlixPartners LLP. If the legal liabilities are not manageable, Mallinckrodt may choose to seek bankruptcy protection, according to Bloomberg sources.

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) shares closed up 23% to $1.56 following the initiation of coverage by H.C. Wainwright with a Buy rating and a $5 price target.

uniQure N.V. (Nasdaq: QURE) announced that it has commenced an underwritten public offering of $200m of its ordinary shares. Shares are trading down 10% to $50.50 after hours.

Ovid Therapeutics Inc. (NASDAQ: OVID) shares closed up 13% to $1.99 following the initiation of coverage by RBC Capital with an Outperform rating and a price target of $12.

Clearside Biomedical, Inc. (Nasdaq: CLSD) shares closed up 16% to $0.68 on news of a license agreement with Regenxbio Inc. (Nasdaq: RGNX) where Regenxbio will be provided with rights to its in-office SCS Microinjector for the delivery of RGX-314 to treat wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR). Clearside will receive up to $34m in total development milestones and up to $102m in sales milestones and mid-single digit royalties on net sales of products using the SCS Microinjector.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares closed up 13% to $2.60 on news of a collaboration with AbbVie, where a Phase 1b trial will be initiated of combinations of ABBV-368 plus tilsotolimod in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Idera will provide clinical trial supply of tilsotolimod to AbbVie and AbbVie will be responsible for conduct of the trial.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


EyeGate Pharmaceuticals, Inc. (EYEG): $2.78; +13%.

Concert Pharmaceuticals, Inc. (CNCE): $1.99; +13%.

Emergent BioSolutions Inc. (EBS): $56.00; +12%.

TCR2 Therapeutics Inc. (TCRR): $18.88; +11%.

Acasti Pharma Inc. (ACST): $1.99; +11%.


Immunic, Inc. (IMUX): $13.20; -17%.

Ardelyx, Inc. (ARDX): $4.96; -15%.

Ultragenyx Pharmaceutical Inc. (RARE): $45.06; -12%.

Brickell Biotech (NASDAQ: BBI): $4.14; -12%.

Tocagen Inc. (TOCA): $3.04; -11%.

Pipeline updates below:

Pipeline Database Updates


Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue